Jump to content

User talk:XyZAn/sandbox

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Alexion Pharmaceuticals

[edit]
Date Acquired company Business acquired for Transaction Value References
Enobia Pharma Corp $110,000,000 [1][2]
Taligen Therapeutics Development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders $610,000,000 + $240,000,000 in contingency payments

Amgen

[edit]
Date Acquired company Business acquired for Transaction Value References
1994 Synergen, Inc. Development & manufacture of protein-based human pharmaceuticals $240,000,000 [3]
2000 Kinetix Pharmaceuticals, Inc. Protein Kinase inhibitors $170,000,000 [4]
2002 Immunex Corporation Arthritis medications $16,000,000,000 [5]
2004 Tularik, Inc. $1,300,000,000 [6]
2006 Abgenix, Inc. $2,200,000,000 [7]
2006 Avidia, Inc. $380,000,000 [8]
2007 Ilypsa, Inc. Late-stage selective phosphate binder for the treatment of Hyperphosphatemia $420,000,000 [9]
2007 Alantos Pharmaceuticals Holdings, Inc. Clinical Stage Dipeptidyl Peptidase IV Inhibitor & Matrix Metalloproteinases Platform $300,000,000 [10]
2011 BioVex Group, Inc. Drug in phase 3 clinical trials for treatment of advances melanoma & head and neck cancer $1,000,0000,000 [11]
2011 Laboratório Químico Farmacêutico Bergamo Ltda.
2012 Micromet, Inc. Novel cancer treatment in clinical trials for hematologic malignancies $1,160,000,000 [12]
2012 Mustafa Nevzat Pharmaceuticals Platform for growth in Turkey $700,000,000 [13]
2012 KAI Pharmaceuticals Includes KAI-4169 program which is in phase 2a clinical results $315,000,000 [14]
2012 deCode Genetics Provides industry leading ability in identification and validation of disease targets in human populations $415,000,000 [15]
2013 Onyx Pharmaceuticals Access to cancer drugs Carfilzomib, Sorafenib, Regorafenib $10,400,000,000 [16]

AstraZeneca

[edit]
Date Company Formed by merger of Business References
1999 AstraZeneca plc Astra AB & Zeneca Group plc
Date Acquired company Business acquired for Transaction Value References
2005 KuDOS Pharmaceuticals £120,000,000 [17]
2006 Cambridge Antibody Technology Antibody therapeutics, primarily using phage and ribosome display technology £702,000,000 [18]
2007 Arrow Therapeutics Discovery and development of anti-viral therapies $150,000,000 [19]
2007 MedImmune Manufacturer of flu vaccines and a respiratory drug for children $15,200,000,000 [20]
2011 Guangdong BeiKang Pharmaceutical Company Injectable medicines to treat infections [21]
2012 Ardea Biosciences Manufacturer of flu vaccines and a respiratory drug for children $1,260,000,000 [22]
2013 Spirogen Ltd (bought by MedImmune unit) Cancer therapies $200,000,000 + $240,000,000 in milestone payments [23]

Biogen Idec

[edit]
Date Company Formed by merger of Business References
2003 Biogen Idec Biogen Inc. & IDEC Pharmaceuticals Specialises in drugs for neurological disorders, autoimmune disorders and cancer.
Date Acquired company Business acquired for Transaction Value References
2006 Conforma Therapeutics Corporation Treatment for fibrosis and core scientific team focused on phase 2 program $150,000,000 + $100,000,000 for mile stone achievements [24]
2006 Fumapharm Develops therapeutics derived from fumaric acid esters for patients with high unmet medical need [25]
2007 Syntonix Multiple pre-clinical programs in hemophilia $40,000,000 + $80,000,000 for milestone achievements [26]
2012 Stromedix Treatment for fibrosis and core scientific team focused on phase 2 program $75,000,000 + $487,500,000 for milestone achievements [27]

Bristol-Myers Squibb

[edit]
Date Acquired company Business acquired for Transaction Value References
2009 Medarex Specializes in therapeutic products based on monoclonal antibodies $2,100,000,000 [28]
2010 ZymoGenetics Products in hepatitis C, cancer and other therapeutic areas $885,000,000 [29]
2010 Inhibitex Inc Products in hepatitis C, cancer and other therapeutic areas $2,500,000,000 [30]
2012 Amylin Pharmaceuticals Inc (bought with AstraZeneca) Products in hepatitis C, cancer and other therapeutic areas $5,300,000,000 [31]

Celgene

[edit]
Date Acquired company Business acquired for Transaction Value References
2000 Signal Pharmaceuticals, Inc. Develops pharmaceuticals that regulate disease-related genes.
2002 Anthrogenesis Biotherapeutics company and cord blood banking.
2008 Pharmion Corporation $2,900,000,000
2009 Gloucester Pharmaceuticals
2012 Avila Therapeutics, Inc. Targeted covalent drugs that treat diseases through protein silencing $350,000,000 + $195,000,000 & $380,000,000 in milestone payments [32]

CSL Ltd=

[edit]
Date Acquired company Business acquired for Transaction Value References
2000 ZLB Bioplasma AG Cite error: There are <ref> tags on this page without content in them (see the help page).
2006 Zenyth Therapeutics (acquired by bioCSL) $108,000,000 [33]
2013 Aventis Behring $500,000,000 + $125,000,000 in deferred payments & $250,000,000 in contingency payments [34][35]


Cubist Pharmaceuticals

[edit]
Date Acquired company Business acquired for Transaction Value References
2011 Adolor Develops constipation treatment $453,000,000 [36]
2013 Trius Therapeutics & Optimer Pharmaceuticals $1,620,000,000 [37]

Gilead Sciences

[edit]
Date Acquired company Business acquired for Transaction Value References
2001 Nexstar Pharmaceuticals Provided sales force and commercialisation team in Europe and Australia, and manufactuing plant in San Dimas, California. $550,000,000 [38]
2003 Triangle Pharmaceuticals Rights to Emtricitabine, component of proftable products; Atripla and Truvada $464,000,000 [39]
2006 Corus Pharma, Inc. Entry into respiratory medicine, especially cystic fibrosis $365,000,000
2006 Myogen, Inc. Solidified Gileads position in pulmonary disease medicine through acquisition of Ambrisentan, Darusentan and Flolan. $2,500,000,000
2006 Raylo Chemicals, Inc. Acquisiton of site in Edmonton, Alberta for clinical studies and commerical products $148,000,000 [40]
2007 Nycomed fr. Altana - Cork Commercial manufacturing site $47,000,000
2009 CV Therapeutics, Inc. Brings in Ranexa (treatment of Cardiovascular disease) and Lexiscan to reinforce cardiovascular medicine $1,400,000,000
2010 CGI Pharmaceuticals Broaden research into kinase biology and chemistry $120,000,000
2010 Arresto Biosciences, Inc. Developmental stage research for treatment of fibrotic diseases and cancer $225,000,000 [41]
2011 Calistoga Pharmaceuticals Reinforcement of oncology and inflammation research areas $375,000,000 [42]
2011 Pharmasset, Inc Allows Gilead to take the lead in HCV with Sofosbuvir $10,400,000,000
2013 YM Biosciences, Inc Brings in drug candidate for Janus Kinase inhibition $510,000,000

Hoffman-La Roche

[edit]
Date Company Formed by merger of Business References
2001 Chugai Pharmaceutical Co. Nippon Roche & Chugai
Date Acquired company Business acquired for Transaction Value References
1995 Syntex Womens health care lines [43]
1997 Tastemaker [44]
1997 Boehringer Mannheim $11,000,000,000 [45]
2000 AVL Medical Instruments division Blood gas and electrolyte analysis [46]
2001 Amira Medical Further strengthens position in Diabetes Care [47]
2003 Igen Rights to Igen's ECL-technology [48]
2005 GlycArt Biotechnology AG Technology for enhancing the efficacy of antibodies 235,000,000 CHF [49]
2007 454 Life Sciences Strengthen presence in ultra-fast gene sequencing $14,900,000 [50]
2007 BioVeris Expand its leading ECL immunochemistry business $600,000,000 [51]
2007 NimbleGen Gain entry into high-growth research microarrray market $272,500,000 [52]
2008 Ventana $3,400,000,000 [53]
2008 Piramed Access to important oncology target with potential for treating major cancers such as breast and lung. $272,500,000 [54]
2008 Genentech $43,700,000,000 [55]
2008 Memory Pharmaceuticals Memory develops innovative drug candidates for the treatment of debilitating central nervous system diseases $50,000,000 [56]
2009 innovatis AG Expansion in cellular analytics €15,000,000 [57]
2010 Medingo Ltd. Expands position in the growing insulin delivery systems market $160,000,000 [58]
2010 BioImagene Tissue-based cancer diagnostics and research $100,000,000 [59]
2011 PVT Global market leader in providing customised automation and workflow solutions for in-vitro diagnostic (IVD) testings €65,000,000 [60]
2011 mtm laboratories AG Global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer €130,000,000 + €60,000,000 in milestone payments [61]
2011 Anadys Pharmaceuticals Expand future treatment options for hepatitis C $230,000,000 [62]
2011 Verum Diagnostica GmbH €11,000,000 + €2,000,000 in milestone payments [63]
2013 Constitution Medical Inc. Highly innovative hematology testing system $220,000,000 [64]


Merck KGaA

[edit]
Date Acquired company Business acquired for Transaction Value References
2006 Serono $13,200,000,000 [65]
2006 Millipore Corporation $7,200,000,000 [66]

Sanofi

[edit]
Date Company Formed by merger of Business References
1995 Hoechst Marion Roussel Hoechst AG, Roussel Uclaf & Marion Merrell Dow
1999 Sanofi-Synthélabo Sanfoi (former subsidiary of Total) & Synthélabo (former subsidiary of L'Oréal)
1999 Aventis Rhône-Poulenc S.A. & Hoechst Marion Roussel
Date Acquired company Business acquired for Transaction Value References
2004 Aventis €54,500,000,000
2010 Genzyme Primarily devoted to finding drugs that would cure enzyme deficiency conditions that were essential to human survival $20,100,000,000 [67]

Teva Pharmaceutical Industries

[edit]
Date Company Formed by merger of Business References
1976 Teva Pharmaceutical Industrie Assia, Zori & Teva
Date Acquired company Business acquired for Transaction Value References
1980 Ikapharm
1999 Copley Pharmaceutical, Inc $220,000,000
2008 CoGenesys, Inc. $400,000,000 [68]
2008 Bentley Pharmaceuticals, Inc. $360,000,000 [69]
2008 Barr Pharmaceuticals, Inc. $7,460,000,000 [70]
2010 ratiopharm €3,625,000,000 [71]
2011 Theramex Women's health and gynecology products
2011 Cephalon, Inc. Key therapeutic areas including CNS, oncology, respiratory and pain management $6,800,000,000 [72]
2011 Taiyo Pharmaceutical Industry Co. Ltd. Position Teva as a leader in the Japanese generics market $460,000,000

Vertex Pharmaceuticals

[edit]
Date Acquired company Business acquired for Transaction Value References
2009 ViroChem Pharma Novel Polymerase Inhibitors $100,000,000 [73]

References

[edit]
  1. ^ http://www.alexionpharma.com/News/article.aspx?relid=646807
  2. ^ http://www.businessweek.com/news/2012-01-04/alexion-to-pay-as-much-as-1-08-billion-to-buy-enobia-pharma.html
  3. ^ http://www.nytimes.com/1994/11/19/business/amgen-to-buy-synergen-a-troubled-rival.html
  4. ^ http://edgar.secdatabase.com/2565/89843000003014/filing-main.htm
  5. ^ http://edition.cnn.com/2001/BUSINESS/12/17/amgen.immunex/
  6. ^ http://www.amgen.com/media/media_pr_detail.jsp?releaseID=509295&year=
  7. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2006&releaseID=837754
  8. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2006&releaseID=910461
  9. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=1011002
  10. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=1012256
  11. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2011&releaseID=1519312
  12. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2012&releaseID=1653062
  13. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2012&releaseID=1686962
  14. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2012&releaseID=1681390
  15. ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2012&releaseID=1765710
  16. ^ http://www.bloomberg.com/news/2013-08-25/amgen-to-buy-onyx-pharaceuticals-for-10-4-billion.html
  17. ^ http://www.telegraph.co.uk/finance/2928954/AstraZeneca-buys-biotech-company-for-120m.html
  18. ^ http://www.telegraph.co.uk/finance/2928954/AstraZeneca-buys-biotech-company-for-120m.html
  19. ^ http://www.marketwatch.com/story/astrazeneca-agrees-to-buy-arrow-therapeutics-for-150-mln
  20. ^ http://uk.reuters.com/article/2007/04/23/uk-medimmune-astrazeneca-idUKN2221194520070423
  21. ^ http://www.pmlive.com/pharma_news/astrazeneca_to_buy_chinese_generics_firm_352964
  22. ^ http://dealbook.nytimes.com/2012/04/23/astrazeneca-to-buy-ardea-for-1-26-billion/
  23. ^ http://www.bloomberg.com/news/2013-10-15/astrazeneca-to-pay-up-to-440-million-for-spirogen.html
  24. ^ http://phx.corporate-ir.net/phoenix.zhtml?c=148682&p=irol-newsArticle&ID=851199&highlight=
  25. ^ http://phx.corporate-ir.net/phoenix.zhtml?c=148682&p=irol-newsArticle&ID=862060&highlight=
  26. ^ http://phx.corporate-ir.net/phoenix.zhtml?c=148682&p=irol-newsArticle&ID=946695&highlight=
  27. ^ http://www.biogenidec.com/press_release_details.aspx?ID=5981&ReqId=1660793
  28. ^ http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aZWoVAXYGSgA
  29. ^ http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquire-zymogenetics
  30. ^ http://dealbook.nytimes.com/2012/01/07/bristol-myers-to-buy-inhibitex-for-2-5-billion/
  31. ^ http://uk.reuters.com/article/2012/06/30/uk-amylin-bristolmyerssquibb-idUKBRE85T01U20120630
  32. ^ http://www.avilatx.com/news/2012_0126_AvilaCelgene.pdf
  33. ^ http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740571/prdetail.htm
  34. ^ http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199941069485/prdetail.htm
  35. ^ http://edition.cnn.com/2003/BUSINESS/12/08/australia.csl.biz/
  36. ^ http://www.bizjournals.com/boston/blog/mass-high-tech/2011/12/cubist-completes-adolor-acquisition-at-about.html
  37. ^ http://www.bloomberg.com/news/2013-07-30/antibiotic-maker-cubist-buys-trius-optimer-for-hospital-drugs.html
  38. ^ http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=_933138351&highlightl
  39. ^ http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=_1038971547&highlightl
  40. ^ http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=_869116&highlight
  41. ^ http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=_1509319&highlight
  42. ^ http://investors.gilead.com/preview/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1531190&highlight=l
  43. ^ http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=_933138351&highlightl
  44. ^ http://www.roche.com/static/app/news/media-news-1997-04-01-e.pdf
  45. ^ http://www.roche.com/static/app/news/media-news-1997-05-26-2-e.pdf
  46. ^ http://www.roche.com/static/app/news/media-news-2000-04-10-e.pdf
  47. ^ http://www.roche.com/static/app/news/media-news-2001-11-07-e.pdf
  48. ^ http://www.roche.com/media/media_releases/med-cor-2003-07-24a.htm
  49. ^ http://www.roche.com/media/media_releases/med-cor-2005-07-26.htm
  50. ^ http://www.roche.com/media/media_releases/med-cor-2007-03-29.htm
  51. ^ http://www.roche.com/media/media_releases/med-cor-2007-04-04.htm
  52. ^ http://www.roche.com/media/media_releases/med-cor-2007-06-19.htm
  53. ^ http://www.roche.com/media/media_releases/med-cor-2008-01-22.htm
  54. ^ http://www.roche.com/media/media_releases/med-cor-2007-06-19.htm
  55. ^ http://www.roche.com/media/media_releases/med-cor-2008-07-21b.htm
  56. ^ http://www.roche.com/media/media_releases/med-cor-2008-11-25.htm
  57. ^ http://www.roche.com/media/media_releases/med-cor-2009-03-16.htm
  58. ^ http://www.roche.com/media/media_releases/med-cor-2010-04-13.htm
  59. ^ http://www.roche.com/media/media_releases/med-cor-2010-08-23.htm
  60. ^ http://www.roche.com/media/media_releases/med-cor-2011-03-15.htm
  61. ^ http://www.roche.com/media/media_releases/med-cor-2011-07-19.htm
  62. ^ http://www.roche.com/media/media_releases/med-cor-2011-10-17.htm
  63. ^ http://www.roche.com/media/media_releases/med_dia_cb_2011-12-02.htm
  64. ^ http://www.roche.com/media/media_releases/med-cor-2013-07-02.htm
  65. ^ http://www.manager-magazin.de/unternehmen/artikel/a-438324.html
  66. ^ http://www.finanznachrichten.de/nachrichten-2010-03/16260319-stocks-news-us-merck-kgaa-to-buy-millipore-for-dollar-6-bln-020.html
  67. ^ http://www.reuters.com/article/2011/02/03/uk-sanofi-genzyme-idUKTRE7121P720110203
  68. ^ http://www.tevapharm.com/Media/News/Pages/2008/1554680.aspx?category=Business%20Development&page=4
  69. ^ http://www.tevapharm.com/Media/News/Pages/2008/1554709.aspx?category=Business%20Development&page=4
  70. ^ http://www.tevapharm.com/Media/News/Pages/2008/1554749.aspx?category=Business%20Development&page=4
  71. ^ http://www.tevapharm.com/Media/News/Pages/2010/1555476.aspx?category=Business%20Development&page=2
  72. ^ http://www.tevapharm.com/Media/News/Pages/2011/1580417.aspx?category=Business%20Development&page=1
  73. ^ http://investors.vrtx.com/releasedetail.cfm?releaseid=368695
Retrieved from "https://en.wikipedia.org/w/index.php?title=User_talk:XyZAn/sandbox&oldid=678799822"